# Safety and Efficacy of Neoantigen-Based Personalized Immunotherapy as Consolidation Therapy After Standard Adjuvant Treatment in Resectable Stage III Colorectal Cancer or Non-Small Cell Lung Cancer

> **NCT07504484** · PHASE1 · COMPLETED · sponsor: **Ying Yuan, MD** · enrollment: 6 (actual)

## Conditions studied

- CRC (Colorectal Cancer)
- Non Small Lung Cancer

## Interventions

- **BIOLOGICAL:** iNeo-Vac-P01

## Key facts

- **NCT ID:** NCT07504484
- **Lead sponsor:** Ying Yuan, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-30
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07504484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07504484, "Safety and Efficacy of Neoantigen-Based Personalized Immunotherapy as Consolidation Therapy After Standard Adjuvant Treatment in Resectable Stage III Colorectal Cancer or Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07504484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*